TABLE 4.
Risk Factors for Loss of Visual Acuity (20/50 or worse) in 92 Eyes with HLA-B27-associated Uveitis
| 20/50 or worse | ||
|---|---|---|
| Predictors | Crude Hazard Ratio (95% CI, P)a | Adjusted Hazard Ratio (95% CI, P)b |
| Duration of uveitis prior to presentation (years) | 0.98 (0.92–1.0, 0.43) | |
| Male | 1.9 (0.68–5.2, 0.22) | 6.0 (2.3–34, 0.001) |
| Caucasian vs other | 2.0 (0.35–11, 0.44) | |
| Chronic disease | 2.6 (0.93–7.7, 0.07) | 6.8 (3.2–37, <0.0001)) |
| HLA-B27 systemic disease | 0.91 (0.33–2.5, 0.87) | |
| Presenting complications | ||
| Posterior Synechiae | 6.2 (2.0–18, 0.001) | 4.0 (2.5–21, <0.0001) |
| Elevated intraocular pressure | 2.4 (0.52–11, 0.25) | |
| Oral corticosteroidsc | 3.4 (1.2–10, 0.03) | |
| Inflammationc | 10 (1.4–2.6, <0.0001) | 6.2 (3.3–33, <0.0001) |
| Corticosteroid-sparing therapyc | 2.7 (0.93–7.8, 0.07) | 2.6 (1.2–14, 0.021) |
| Topical corticosteroidsc | 3.9 (1.0–15, 0.04) | |
| Corticosteroid injectionsc | 6.5 (2.7–35.7, 0.001) | 5.1 (5.4–27, <0.0001) |
a
Crude HR = hazard ratio (95% CI = 95% confidence interval, P value) for univariate Cox proportional hazard model using robust feature.
b
Adjusted HR = hazard ratio (95% CI = 95% confidence interval, P value) for multivariate analyses in which all exposure variables were included and stepwise regression was utilized to eliminate all variables with P values ≥0.10
c
Time-updated variables